The concept of cardioreparation: Part 2. medical implications of cardioreparation

European Journal of Cardiovascular Prevention & Rehabilitation

Volumn 3, Issue 3, 1996, Pages 287-293

  Cleland, John G f ^a   Dewhurst, Neil G ^b   Murphy, Richard L W ^c   Boudier, Harry A J Struijker ^d   Tan, Lip Bun ^e   Visser, C A ^f  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b TORBAY HOSPITAL   (United Kingdom)

^c Oxford Bioresearch Laboratory   (United Kingdom)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOLYTIC AGENT; INOTROPIC AGENT; NITRIC ACID DERIVATIVE; VASODILATOR AGENT; ANTIHYPERTENSIVE AGENT;

ACUTE HEART INFARCTION; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; PRIORITY JOURNAL; TISSUE INJURY; FEMALE; HEART INFARCTION; MALE; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR;

ANTIHYPERTENSIVE AGENTS; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MYOCARDIAL INFARCTION; RISK FACTORS;

EID: 0029658118     PISSN: 17418267     EISSN: 17418275     Source Type: Journal    
DOI: 10.1177/174182679600300305     Document Type: Article

References (69)

1. Kannel WB: Epidemiological implications of left ventricular hypertrophy In Left Ventricular Hypertrophy and its Regression. Edited by Cruickshank JM Messerli FH. London: Science Press; 1992.
2. Weber KT Brilla CG Cleland JGF etal: Cardioreparation and the concept of modulating cardiovascular structure and function Blood Pressure 1993, 2: 6-21.
3. Fisch C: Electrocardiography and vectorcardiography. In Heart Disease: A Textbook of Cardiovascular Medicine. 4th Edition. Edited by Braunwald E. Philadelphia: WB Saunders; 1992.
4. McMahon SW Wilcken EL MacDonald GJ: The effect of weight reduction on left ventricular mass: A randomized controlled trial in young, overweight hypertensive patients N Engl J Med 1986, 314: 334-339.
5. Levy D Anderson KM Savage DD Kannel WB Christiansen JC Castelli WP: Echocardiographically detected left ventricular hypertrophy: Prevalence and risk factors: The Framingham Heart Study Arch Intern Med 1988, 198: 7-13.
6. Weber KT Brilla CG: Pathological hypertrophy and cardiac interstitium: Fibrosis and the renin-angiotensin-aldosterone system Circulation 1991, 83: 1849-1865.
7. Dahlöf B Pennert K Hansson L: Reversal of left ventricular hypertrophy in hypertensive patients: A metaanalysis of 109 treatment studies Am J Hypertens 1992, 5: 95-110.
8. Fagard R Lijnen P Staessen J Thijs L Amery A: Mechanical and other factors relating to left ventricular hypertrophy Blood Pressure 1994, 1 (suppl):5-10.
9. Cruickshank JM etal: Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy J Hum Hypertens 1992, 6: 85-90.
10. Trimarco B De Luca N Ricciardelli B etal: Cardiac function in systemic hypertension before and after reversal of left ventricular hypertrophy Am J Cardiol 1988, 62: 745-750.
11. Gerstenblith G Schulman SP: Influence of left ventricular mass regression on cardiac function in hypertensive elderly individuals Eur J Clin Pharmacol 1990, 39 (suppl 1):S25-S28.
12. Koren MJ Win RJ Laragh JH Devereux RB: Reduction in left ventricular mass during treatment of essential hypertension is associated with improved prognosis [abstract] Am J Hypertens 1991, 4: 1A-2A.
13. Motz W Schwartzkopf B Vogt M: Hypertensive heart disease: Cardio-reparation by reversal of interstitial collagen in patients Eur Heart J 1995, 16 (suppl C):69-73.
14. White WB Gey HM Schulman P: Assessment of the daily blood pressure load as a determinant of cardiac function in patients with mild-to-moderate hypertension Am Heart J 1989, 118: 782-795.
15. Herpin D Conte D: Assessment of the antihypertensive effect of lisinopril using 24-hour ambulatory monitoring J Hum Hypertens 1989, 3: 11-15.
16. Kloner RA Ellis SG Lange R Braunwald E: Studies of experimental coronary artery reperfusion. Effects on infarct size, myocardial function, biochemistry, ultrastructure and microvascular damage Circulation 1983, 68: 18-25.
17. Jugdutt BI Warnica JW: Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion and complications: Effect of timing, dose and infarct location Circulation 1988, 78: 906-919.
18. Sharpe N Murphy J Smith H Hannan S: Treatment of patients with symptomless left ventricular dysfunction following myocardial infarction Lancet 1988, i: 255-259.
19. The International Collaborative Study Group: Reduction of infarct size with the early use of timolol in acute myocardial infarction. N Engl J Med 1984; 310: 9-15.
20. The MIAMI Trial Research Group: Metoprolol in acute myocardial infarction (MIAMI): A randomized placebo-controlled international trial Eur Heart J 1985, 6: 199-226.
21. ISIS-1 (First International Study of Infarct Survival) Collaborative Group: Randomized trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction. ISIS-I Lancet 1986, ii: 57-66.
22. Yusuf S Wittes J Friedman L: Overview of results of randomized clinical trials in heart disease, I: Treatment following myocardial infarction JAMA 1988, 260: 2088-2093.
23. Yusuf S Peto R Lewis J Collins R Sleight P: Beta blockade during and after myocardial infarction: An overview of the randomized trials Prog Cardiovasc Dis 1985, 27: 335-371.
24. Rona G: Catecholamine cardiotoxicity J Mol Cell Cardiol 1985, 17: 291-306.
25. Cleland JGF: The renin-angiotensin system in heart failure Herz 1991, 16: 68-81.
26. Gundersen T: Secondary prevention after myocardial infarction: Subgroup analysis of patients at risk in the Norwegian timolol multicentre study Clin Cardiol 1985, 8: 253-265.
27. Beta-Blocker Pooling Project Research Group: The Beta-Blocker Pooling Project (BBPP): Subgroup findings from randomized trials in post-infarction patients Eur Heart J 1988, 9: 8-16.
28. Goldbourt U Behar S Reichar-Reiss H Zion M Mandelzweig L Kaplinsky E: Early administration of nifedipine in suspected acute myocardial infarction: The Secondary Prevention Reinfarction Israel Nifedipine Trial 2 Study Arch Intern Med 1993, 153: 345-353.
29. Fifer MA Colucci WS Lorell BH Jaski BE Barry WH: Inotropic, vascular and neuroendocrine effects of nifedipine in heart failure: Comparison with nitroprusside J Am Coll Cardiol 1985, 5: 731-737.
30. Multicenter Diltiazem Postinfarction Trial Research Group: The effect of diltiazem on mortality and reinfarction after myocardial infarction N Engl J Med 1988, 319: 385-392.
31. Danish Study Group on Verapamil in Myocardial Infarction: Verapamil in acute myocardial infarction Eur Heart J 1984, 5: 516-528.
32. Pfeffer MA Braunwald E Moyé LA Basta L Brown EJ Jr Cuddy TE etal: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement Trial N Eng J Med 1992, 327: 669-677.
33. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure Lancet 1993, 342: 821-828.
34. The TRACE study group: The TRAndalopril Cardiac Evaluation (TRACE) study: Rationale, design, and baseline characteristics of the screened population Am J Cardiol 1994, 73: 44C-50C.
35. Gruppo Italiano per lo Studio della Soppravvivenza nell'Infarto Miocardico: GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate, singly and together, on 6-week mortality and ventricular function after acute myocardial infarction Lancet 1994, 343: 1115-1120.
36. Schipperheyn JJ: GISSI 3: The results after six months Cardiologie 1994, 1: 384-386.
37. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group: ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction Lancet 1995, 345: 669-685.
38. Chinese Cardiac Study Collaborative Group: Oral captopril versus placebo among 13 634 patients with suspected acute myocardial infarction: Interim report from the Chinese Cardiac Study (CCS-1) Lancet 1995, 345: 686-687.
39. Ambrosioni E Borghi C Magnani B: The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction N Engl J Med 1995, 332: 80-85.
40. Swedberg K Held P Kjekshus J Rasmussen K Ryden L Wedel H: Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: Results of the Cooperative New Scandinavian Enalapril Survival Study (CONSENSUS-II) N Engl J Med 1992, 327: 678-684.
41. Kingma JH van Gilst WH Peels CH, For the CATS investigators: Acute intervention with captopril and thrombolysis study (CATS) Eur Heart J 1994, 15: 898-907.
42. Hochman JS Edelstein R Palmeri S etal: Captopril before reperfusion in acute myocardial infarction: The CAPTIN experience [abstract] J Am Cardiol 1993, 21: 37A.
43. Schoemaker RG Debets JJM Struyker-Boudier HAJ Smits JFM: Delayed but not immediate captopril therapy improves cardiac function in conscious rats, following myocardial infarction J Mol Cell Cardiol 1991, 23: 187-197.
44. Packer M: The neurohumoral hypothesis: A theory to explain the mechanism of disease progression in heart failure J Am Coll Cardiol 1992, 20: 248-254.
45. McFate Smith W: Epidemiology of congestive heart failure Am J Cardiol 1985, 55: 3A-8A.
46. Goldberg AD Goldstein S Nicklas J, For the Imazodan Study group: Multicenter trial of imazodan in patients with chronic congestive heart failure [abstract]. Circulation 1990, 80 (suppl III):III-673.
47. Packer M Medina N Yushak M: Haemodynamic and clinical limitation of long-term inotropic therapy with amrinone in patients with severe chronic heart failure Circulation 1984, 70: 1038-1047.
48. Packer M Carver JR Rodeheffer RJ Ivanhoe RJ DiBianco R Zeidiss M etal: Effect of oral milrinone on mortality in severe chronic heart failure N Engl J Med 1991, 325: 1468-1475.
49. Ferguson DW Berg WJ Sanders JS Roach PJ Kempf JS Kienzle MG: Sympatho-inhibitory responses to digitalis glycosides in heart failure patients: Direct evidence from sympathetic neural recordings Circulation 1989, 80: 65-77.
50. Covit AB Schaer GL Sealey JE Laragh JH Cody RJ: Suppression of the renin-angiotensin system by intravenous digoxin in chronic congestive heart failure Am J Med 1983, 75: 445-447.
51. Guyatt GH Sullivan MJJ Fallen EL Tibal H Rideout E Halcrow S etal: A controlled trial of digoxin in congestive heart failure Am J Cardiol 1988, 61: 371-375.
52. de Bono D: Digoxin in eurhythmic heart failure: PROVED or not proven? Lancet 1994, 343: 128-129.
53. Cohn JN Archibald DG Ziesche S Franciosa JA Harstan WE Tristani FE etal: Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veterans Administration Cooperative Study N Engl J Med 1986, 314: 1547-1552.
54. Cleland JGF Oakley CM: Vascular tone in heart failure: The neuroendocrine-therapeutic interface Br Heart J 1991, 66: 264-267.
55. Waagstein F Bristow MR Swedberg K Camerini F Fowler MB Silver MA etal: Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy Lancet 1993, 342: 1441-1446.
56. CIBIS Investigators and Committees: A randomized trial of ß-blockade in heart failure: The Cardiac Insufficiency Bisoprolol Study (CIBIS) Circulation 1994, 90: 1765-1773.
57. Packer M Bristow MR Cohn JN For the US Carvedilol Heart Failure Study Group: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure N Engl J Wed 1996, 334: 1349-1355.
58. Elkayam U Amin J Mehra A Vasquez J Weber L Rahimtoola SH: A prospective, randomized, double-blind crossover study to compare the efficacy and safety of chronic nifedipine therapy to isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure Circulation 1990, 82: 1954-1961.
59. Goldstein RE Boccuzi SJ Cruess D Nattel S, The Adverse Experience Committee, and the Multicentre Diltiazem Post-infarction Research Group: Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction Circulation 1991, 83: 52-60.
60. Colucci WS Fifer MA Lorell BH Wynne J: Calcium channel blockers in congestive heart failure: Theoretic considerations and clinical experience Am J Wed 1985, 78 (suppl 2B):9-17.
61. SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure N Engl J Med 1991, 325: 293-302.
62. The CONSENSUS trial study group: Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) N Engl J Med 1987, 316: 1429-1435.
63. Cohn JN Johnson G Ziesche S Cobbe F Francis G Tristani FE etal: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure N Engl J Med 1991, 325: 303-310.
64. Tan L.B. Jalil JE Pick R Janicki JS Weber KT: Cardiac myocyte necrosis induced by angiotensin II Circ Res 1991, 69: 1185-1195.
65. Cleland JGF Dargie HJ Hodsman GP etal: Captopril in heart failure. A double-blind controlled trial Br Heart J 1984, 52: 530-535.
66. Bristow MR Abraham WT: Anti-adrenergic effects of angiotensin converting enzyme inhibitors Eur Heart J 1995, 19 (suppl K):37-41.
67. Wiemer G Scholkens BA Becker RH Busse R: Ramiprilat enhances endothelial autocoid formation by inhibiting breakdown of endothelial derived bradykinin Hypertension 1991, 18: 558-563.
68. Costentino F Lüscher TF: Maintenance of vascular integrity: Role of nitric oxide and other bradykinin mediators Eur Heart J 1995, 19 (suppl K):4-12.
69. Schipperheijn JJ: The ATLAS study, [in Dutch] Tijdschrift voor Therapie Geneesmiddel en Onderzoek 1993, 18: 111-113.